Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8,942
datasets available to search
ShareScore release 0.9.0
Dataset results
8,942 results for “prostate”
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.
<p>This file contains vst-normalized gene expression data along with annotations which can be used to reproduce our findings.</p>
Data to reproduce analysis in the WCDT metastatic prostate tumor subtypying paper
<p>Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation AR-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration resistant prostate cancer (mCRPC), defined by whether the tumor expresses either AR or neuroendocrine markers. Among the subtypes of mCRPC, the molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterize genomic and epigenomic features of treatment-emergent mCRPC subtypes in 210 tumors by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing. We show that AR-/NE- tumors exhibit a clinically and molecularly distinct phenotype. Patients with AR-/NE- mCRPC tumors have the shortest survival, and these tumors preferentially harbor amplification of the chromatin remodeler <em>CHD7</em> and loss of <em>PTEN</em>. We demonstrate that methylation changes in <em>CHD7</em> candidate enhancers are linked to elevated <em>CHD7</em> expression in AR-/NE+ tumors. Moreover, we use genome-wide methylation analysis to nominate the Krüppel-like factor gene <em>KLF5</em> as a driver of the AR-/NE- phenotype and link its activity to loss of the tumor supressor <em>RB1</em>. These observations reveal the aggressiveness of the AR-/NE- tumors and elucidate genomic and epigenomic drivers of mCRPC subtypes, which may facilitate the identification of novel therapeutic targets in this highly aggressive disease.</p>
Mass spectrometry- based biomarkers to detect prostate cancer: A multicentric study based on non- invasive urine collection without prior intervention
<p>These are datasets related to mass spectrometry proteomics analysis, in particular Capillary Electrophoresis coupled to Mass Spectrometery (CE-MS). CE-MS was employed to acquire proteomics profiles from 970 patients from two different clinical centers. with the aim to develop a biomarker model to detect Prostate Cancer. </p>
Prostate MRI T2-weighted images with peripherial and trasition zone segmentations including corresponding PIRADS and PSA values
<p>This dataset contains 114 t2-weighted MRI images of the prostate with corresponding segmentations.The segmentations include two labels, 1 - Transition Zone, 2 - Peripherial Zone. Most of the images include corresponding PIRADS and PSA values, which are available in the file PSA_PIRADS.csv.</p> <p>For more information concerning the images, see the following article.</p> <p>Please cite the following articles, if you are using this dataset:</p> <p>Gibala, S.; Obuchowicz, R.; Lasek, J.; Schneider, Z.; Piorkowski, A.; Pociask, E.; Nurzynska, K. Textural Features of MR Images Correlate with an Increased Risk of Clinically Significant Cancer in Patients with High PSA Levels. <em>J. Clin. Med.</em> <strong>2023</strong>, <em>12</em>, 2836. https://doi.org/10.3390/jcm12082836</p> <p>Gibała, S.; Obuchowicz, R.; Lasek, J.; Piórkowski, A.; Nurzynska, K. Textural Analysis Supports Prostate MR Diagnosis in PIRADS Protocol. <em>Appl. Sci.</em> <strong>2023</strong>, <em>13</em>, 9871. https://doi.org/10.3390/app13179871</p>
Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility
<p>Full results datasets for Proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility:</p> <p>ALL*all_pheno.csv are TOPMed-MESA combined-ancestry models, discovery and replication cohorts</p> <p>ARIC_EA_all_pheno.csv is ARIC European-American ancestry models, discovery cohort</p> <p>ARIC*meta_all.txt is ARIC European-American ancestry models, discovery and replication cohorts, with meta-analysis of disc+rep</p>
Automated diagnosis of prostate cancer using artificial intelligence. A systematic literature review. Extraction and Summary Forms.
<p>Extraction and summary forms of a systematic literature review protocol detailed by Barbara Kitchenham for automated diagnosis of prostate cancer using artificial intelligence articles. </p>
Search strategies for generic justification of 18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent and metastatic prostate cancer
<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project. The search strategies address the following research questions:</p> <p>RQ 1: In the primary staging of patients with high risk prostate cancer, what is the sensitivity, specificity and diagnostic accuracy of 18F-PSMA?</p> <p>RQ 2: In patients with biochemically recurrrent prostate cancer, what is the sensitivity, specificity and diagnostic accuracy of 18F-PSMA?</p> <p>RQ 3: What is the risk of adverse events (including dose) associated with receiving 18F-PSMA?</p> <p>RQ 4: Is 18F-PSMA uptake associated with response to treatments for metastatic prostate cancer?</p>
Single Cell RNA sequencing data of ADT treated Prostate cancer patients
<p>The data was generated from a study that was conducted according to guidelines approved by the Review Board at the University of Texas Southwestern Medical Center. We procured patient biopsy samples from two distinct studies. The first is titled "Tissue Collection and Results Gathering for Radiotherapy Patients & Healthy Individuals" (STU 072010-098), and the second is a Phase I Clinical Study on Stereotactic Ablative Radiotherapy (SABR) for Pelvic and Prostate Areas in High-Risk Prostate Cancer Patients (STU062014-027). The single-cell RNA sequencing (scRNA-seq) took place in Dr. Douglas Strand's laboratory, adhering to the method outlined in Henry et al<sup>1</sup>. We used a 1-hour treatment with 5mg/ml of collagenase type I, 10mM of ROCK inhibitor, and 1mg of DNase. Barcode labeling for 3' GEX was done using a 10X machine, and the sequencing process utilized an Illumina NextSeq 500 device.</p> <p> </p> <p>1. Henry, G. H., Malewska, A., Joseph, D. B., Malladi, V. S., Lee, J., Torrealba, J., ... & Strand, D. W. (2018). A cellular anatomy of the normal adult human prostate and prostatic urethra. <em>Cell reports</em>, <em>25</em>(12), 3530-3542.</p>
Search strategies for 177 lu-PSMA in the treatment of metastatic castrate-resistant prostate cancer
<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project. The search strategies were designed to answer the following research questions:</p> <p><strong>RQ1.</strong> Does the use of radioligand therapy using <sup>177</sup>Lu-PSMA lead to improved overall survival and progression-free survival, compared with other available treatment(s) in patients with metastatic, castrate-resistant prostate cancer?</p> <p><strong>RQ2.</strong> Does the use of radioligand therapy using <sup>177</sup>Lu-PSMA lead to improved quality of life or symptom control, compared with other available treatment(s), in patients with metastatic, castrate-resistant prostate cancer?</p> <p><strong>RQ3. </strong> What is the risk of adverse events and toxicity associated with radioligand therapy using <sup>177</sup>Lu-PSMA, compared with other available treatment in patients with metastatic, castrate-resistant prostate cancer?</p>
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
ClinicalTrials.gov study NCT00224120. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
ClinicalTrials.gov study NCT01338792. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov study NCT02215161. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
ClinicalTrials.gov study NCT00116142. IPD Sharing: NO. Countries: 1. Publications: 4.
The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer
ClinicalTrials.gov study NCT00487721. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
ClinicalTrials.gov study NCT00519285. IPD Sharing: Not stated. Countries: 31. Publications: 3.
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
ClinicalTrials.gov study NCT02199197. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes
ClinicalTrials.gov study NCT03432897. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
ClinicalTrials.gov study NCT03085095. IPD Sharing: NO. Countries: 22. Publications: 3.
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
ClinicalTrials.gov study NCT02499835. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
ClinicalTrials.gov study NCT00676650. IPD Sharing: Not stated. Countries: 22. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.